The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Helio Genomics and Halub Medical Co. Announce Strategic Partnership to Commercialize HelioLiver Dx in The Gulf Cooperation Council and Middle East
Oct 25, 2024•over 1 year ago
Contract Type
partnership
IrvineBiotechnology
Description
Helio Genomics has announced a strategic partnership with Halub Medical Co. to commercialize HelioLiver Dx in Saudi Arabia and The Gulf Cooperation Council (GCC). The partnership aims to introduce the breakthrough liver cancer screening test to the Middle East region, with the test expected to be commercially available in Q1 2025, generating over $10 million dollars in revenue for Helio Genomics.
Company Information
Company
Helio Genomics
Location
Irvine, California, United States
About
Helio Genomics is an AI-driven healthcare company on a mission to save lives by developing technology that can detect cancer early from a simple blood draw. We are pioneers of a true multi-modal x multi-omics approach to biomarker discovery – optimizing the best combination of biological data to unveil a clear picture of how cancer exists and evolves. In doing so, we challenge cancer by translating those learnings into user-friendly, accessible tools that guide medical decision-making to prevent cancer from progressing.
IrvineBiotechnology